Provectus Biopharmaceuticals Inc., of Knoxville, Tenn., completed development of the protocol for a phase Ib/II trial of its investigational cancer therapy PV-10 in combination with the anti-PD-1 immune checkpoint inhibitor Keytruda (pembrolizumab, Merck & Co. Inc.) in patients with stage IV melanoma.